Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.

Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter.

[The effect of alternative therapies on symptoms of patients with functional chest pain--pilot study with Johrei healing technique].

Aim Of The Study: was to determine the efficacy of Johrei as compared to wait-list in improving symptoms of FCP patients.

Material And Methods: Patients with chest pain of noncardiac origin for at least 3 months were enrolled into the study. All patients had to have negative upper endoscopy, pH testing and oesophageal manometry prior to randomization.